Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydolase (SEH) polymorphims in African-Americans with hypertension (HTN)

Abstract

Background CYP2C8, CYP2C9, CYP2J2 and sEH have been shown to be involved in the formation and metabolism of vasoactive epoxides of the epoxygenase pathway which have been proposed to play a role in the pathogenesis of hypertension. Methods We studied the frequency of CYP2C8*2,*3, CYP2C9*2,*3, *4, *5,*8 and *11, sEH R287Q and anR403insertion, and CYP2J2*2-*7 and the newly identified CYP2J2 polymorphisms R49S, L50L, V113M, N124S in 105 AA HTN patients with normal kidney function and 101 healthy AA to determine whether there is a significant difference in prevalence rates of these polymorphisms. The mean age of the HTN patients was 49.3± 12.1 years (mean± sd) and the healthy AA was 38.6± 9.1years. The HTN patients and healthy subjects were 50.4 % and 38.6 % female, respectively. The DNA was isolated from peripheral blood mononuclear cells and then genotyped for the variant alleles using TaqMan-based allelic discrimination assays. Results The prevalence of the CYP2J2 variant alleles with the exception of CYP2J2*7 (table) ranged from 0 to 1.1% in the healthy and HTN populations. Additional results are shown in the table below. Conclusions There was no significant difference in prevalence rates of the CYP2C8, CYP2C9, CYP2J2, and sEH alleles in AA with HTN compared with the healthy AA population. Clinical Pharmacology & Therapeutics (2005) 77, P58–P58; doi: 10.1016/j.clpt.2004.12.110 Table 1. Epoxygenase Variant Allele Frequencies in AA with HTN Variant Allele N Healthy % N HTN P chi-square CYP2C8*2 101 15.3 105 12.3 NS 2C8*3 2.5 2.5 NS CYP2C9*2 101 2.5 105 2.9 NS 2C9*3 2.0 3.3 NS 2C9*8 3.0 1.9 NS 2C9*11 1.0 1.0 NS 2J2*7 95 11.1 90 10.6 NS sEH R287Q 100 8.0 105 7.1 NS sEH R403ins 2.0 1.9 NS